B. Riley Lowers PDS Biotechnology Price Target to $3, Keeps Buy Rating

miércoles, 26 de noviembre de 2025, 8:43 am ET1 min de lectura
PDSB--

B. Riley lowered PDS Biotechnology's price target to $3 from $5, keeping a Buy rating on the shares. The firm believes the shares remain attractively valued, considering the recent strategic pivot's impact on enrollment size, efficacy endpoint durations, and an enriched p16+ve population with limited competing trials.

B. Riley Lowers PDS Biotechnology Price Target to $3, Keeps Buy Rating

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios